Infection Surveillance Solutions Market - Global Industry Insights, Size, Share and Growth till 2023

Infection is the invasion and multiplication of microorganisms such as viruses, bacteria and parasites that are not normally present within the human body. An infection may cause no symptoms and be hidden, or it may cause symptoms and be clinically visible. An infection may remain localized, or it may spread through the blood or lymphatic vessels to become systemic (present in the entire body). The global infection surveillance solutions market is growing due to the emergence of diseases caused by microorganisms that were previously not known. The microorganisms living naturally within the body are not considered as infectious for example, bacteria that normally live within the mouth and intestine such as E. coli do not cause an infection to the body. Hospital associated infections such as urinary tract infection, surgical site infections and pneumonia are increasing due to the use of contaminated devices, patient clothing, and other materials used in hospitals and clinics. This has thus provoked healthcare professionals and hospitals to adopt infection surveillance solutions to identify possible infections during the time the patient remains in hospital, and to develop necessary preventive measures for the same. These infection surveillance solutions also aid in diagnosing antibiotic resistant organisms (AROs) and infections due to non-sterile medical devices.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/infection-surveillance-solutions-market/report-sample

Geographically, North America accounts for the largest market share in the global infection surveillance solutions market, which is attributable to the increasing occurrence of HAIs, favorable government policies for preventing HAIs, and rising healthcare expenditure in this region. Asia-Pacific region is expected to record the highest growth in the global market on account of rising incidences of HAIs, increased awareness and accessibility to advanced healthcare facilities, rising healthcare spending, and rapid improvement in the health insurance sector in this region.

Various players in the infection surveillance solutions market are focusing on collaborating with other companies to expand their product and service offerings as well as introduction of new treatment methods into the infection surveillance solutions market.

In June, 2017, BD MAX, a newly developed molecular test of Becton, Dickinson and Company, received 510(k) clearances from the U.S. Food and Drug Administration (FDA) for detecting intestinal bacteria that causes infectious diarrhea. The BD MAX was aimed at detecting majority of pathogens that cause acute gastroenteritis, ultimately leading to hospitalization.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=infection-surveillance-solutions-market

In June, 2017, Wolters Kluwer announced that Point of Care (POC) Advisor, its real-time clinical surveillance and analytics platform, was to integrate the Natural Language Processing (NLP) solution from Hiteks Solutions, Inc. for inclusion of unstructured and structured documentation to make them immediately come into action. The purpose of the integration was to enable real-time analysis of physician notes for infection sources, presence of one or more diseases occurring at the same time and other clues to the presence of sepsis.

Some of the other key players in global market are, Premier Inc., Baxter International Inc., Gojo Industries, Inc., Truven Health Analytics (An IBM Company), DEB Group Ltd., Hygreen, Inc., Atlas Medical Software, and RL Solutions.

Acromegaly Therapeutics Pipeline Review 2018

Acromegaly is a type of hormonal disorder that causes excessive release of growth hormone from pituitary gland in the body. Acromegaly is generally diagnosed in middle aged adults. Some of the complications associated with acromegaly are increased risk of cardiovascular disease, high blood pressure, arthritis, type 2 diabetes, and colon polyps. One of the common symptoms of acromegaly is abnormal growth of hands and feet. In addition, release of excess growth hormone is observed in noncancerous tumours of pituitary gland which is called adenomas. Amryt Pharma plc is in the process of developing AP102 as a growth factor receptor antagonist for the treatment of acromegaly. Strongbridge Biopharma plc is in the process of developing veldoreotide as a somatostatin analogue for the treatment of acromegaly. Some of the companies having the pipeline of acromegaly include Midatech Pharma Plc, Strongbridge Biopharma plc, and others.

Explore Report at: https://www.psmarketresearch.com/market-analysis/acromegaly-therapeutics-pipeline-analysis

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Explore Report sample at: https://www.psmarketresearch.com/market-analysis/acromegaly-therapeutics-pipeline-analysis/report-sample

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Neisseria Gonorrhoeae Infections Therapeutics - Pipeline Review 2018

Neisseria gonorrhoeae infections is a sexually transmitted disease that is caused by Neisseria gonorrhoeae bacterium which cause infections in throat, rectum, and genitals. In men, the observed symptoms of gonorrhoeae infections are burning sensation during urination, painful and swollen testicles, and white, green or yellow discharge from the penis. In women, the observed symptoms of gonorrhoeae are vaginal bleeding during periods, increased vaginal discharged, and burning sensation during urination. The unprotected vaginal, oral or anal sex are the risk factors for gonorrhoeae infections. Entasis Therapeutics, Inc. is in the process of developing ETX0914 as a bacterial type II topoisomerases inhibitor, for the treatment of gonorrhoeae infections. Therapyx, Inc. is also in the process of developing IL12 NanoCap for the treatment of gonorrhoeae infection. Some of the companies having the pipeline of neisseria gonorrhoeae infections include Therapyx, Inc., Entasis Therapeutics, Inc., and others.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/neisseria-gonorrhoeae-infections-therapeutics-pipeline-analysis/report-sample

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Explore Report at: https://www.psmarketresearch.com/market-analysis/neisseria-gonorrhoeae-infections-therapeutics-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Melasma Therapeutics Clinical Trials Review 2018

Melasma, also known as chlosma, is characterized by localized, chronic acquired hypermelanosis of the skin that occur due to melanogenesis dysfunction. It is characterized by the appearances of brown macules distributed symmetrically on the sun-exposed area of the body. It generally occurs due to more use of dermatological care products. The disease affects the quality of life of patient, due to frequent facial involvement. Some of the risk factor associated with the disease are pregnancy, sexual hormones, sun exposure, sue of cosmetics, photosensitizing drugs, steroids and inflammatory process of the skin. Patients generally feels lack of motivation to go out, anhedonia, low-self-esteem, dissatisfaction and feeling of shame. The University of Pittsburgh is in the process of developing TCA peel for the treatment of melisma. Allergan, Inc. is in the process of developing hydroquinone topical cream for the treatment of melisma. Some of the companies and universities having the pipeline of melisma include Allergan, Inc., Assiut University, University of Pittsburgh, and others.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/melasma-therapeutics-pipeline-analysis/report-sample

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Explore Report at: https://www.psmarketresearch.com/market-analysis/melasma-therapeutics-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Pre-Eclampsia Therapeutics - Pipeline Review 2018, Clinical Trials & Results, Patent and Developments

Pre-eclampsia is a disorder of high blood pressure that causes decrease in blood supply to the growing foetus. The disease can be severe if left untreated, and can cause seizure or coma to the patient, a condition called as eclampsia. One of the complication associated with pre-eclampsia is HELLP syndrome which is characterized by low platelet count, hemolysis, and elevated liver enzymes. Some of the risk associated with pre-eclampsia that affects foetus are lack of nutrients and oxygen, preterm birth, and stillbirth. According to the Preeclampsia Foundation, each year, around 10,500 infants die in the U.S. A1M Pharma AB is in the process of developing A1M as a free radical scavenger, for the treatment of pre-eclampsia. VG Life Sciences Inc. is also in the process of developing VG 1177 as an immunomodulator, for the treatment of pre-eclampsia. Some of the companies and universities having the pipeline of pre-eclampsia include University of Pittsburgh, VG Life Sciences Inc., and others.

Explore Report at: https://www.psmarketresearch.com/market-analysis/pre-eclampsia-therapeutics-pipeline-analysis

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/pre-eclampsia-therapeutics-pipeline-analysis/report-sample

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Fungal Infections - Pipeline Review 2018

The fungal infection pipeline has more than 60 drugs. In pipeline analysis, drugs are analyzed based on route of administration and molecule type. The pipeline is also analyzed on the basis of monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-clinical stage.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/fungal-infections-pipeline-analysis/report-sample

Phase III clinical trial known for the comparison of new treatments with the standard treatment in which the safety, efficacy and side effects of new intervention is compared with the already existing treatment. The Phase III clinical trial takes around 2-3 years to complete and the total number of participants vary from 100-1,000. After the completion of Phase III stage, the company filed New Drug Application to the regulatory authorities known as filed stage. There are 3 drugs for fungal infection in Phase III clinical trial. Terbinafine, also known as MOB-015, is a drug candidate of Moberg Pharma AB. The drug candidate is being developed for the treatment of onychomycosis. In fungal infection, no drugs have been registered for NDA filing.

VT-1161, a phase II drug candidate of Viamet Pharmaceuticals, Inc. for the treatment of onychomycosis (Fungal Infection) and recurrent vulvovaginal candidiasis. Phase II clinical trial is the second phase that answer safety, efficacy and dosing of the new intervention. There are total 14 drugs present in phase II trial of fungal infections. Phase II clinical trial take around 2 years to complete and between 100 – 120 patients participate in the Phase II trial.

Explore Report at: https://www.psmarketresearch.com/market-analysis/fungal-infections-pipeline-analysis

PC945 is under development by Pulmocide Ltd. for the prevention and treatment for aspergillosis in cystic fibrosis, lung transplant and allergic bronchopulmonary aspergillosis. The drug candidate targets the cytochrome P450 C-14 alpha demethylase (CYP51) and inhibits its action. There are 8 drugs present in Phase I clinical stage. In Phase I clinical trial, safety of the new intervention is determined. The trial takes around 1-2 years to complete and the total number of volunteers participating in the trial vary between 15 – 30.

Pipeline analysis provides description about the key companies developing fungal infections drugs. Some of the key players actively involved in the research and development are Moberg Pharma AB, Viamet Pharmaceuticals, Inc., Pulmocide Ltd., Vyom Biosciences, NovaDigm Therapeutics Inc., Matinas BioPharma Holdings Inc., Sol-Gel Technologies Ltd. and Eisai Co. Ltd.

Browse Other Related report at: https://www.psmarketresearch.com/industry-report/pharmaceuticals

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Ocular Pain Treatment Market - Pipeline Analysis, Development and Growth, 2023

The global ocular pain treatment market is expected to witness considerable growth due to increasing awareness about the eye disorders, technological advancement in ocular therapeutic and diagnostic test, and increasing number of lifestyle related ocular diseases. In addition, increasing geriatric population and increasing disposable income are further supporting the growth of the global ocular pain market.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/ocular-pain-treatment-market/report-sample

The pharmaceutical companies are actively involved in the research and development of drugs for ocular pain. Loteprednol etabonate, a Mucus-Penetrating Particle platform technology based Phase III clinical trial drug of Kala Pharmaceuticals, Inc., is nanotechnology based products for the treatment of ocular pain.

Ocular pain is defined as the inflammation of middle layer of eye known as uvea. It can develop in optic nerve, blood vessels, muscles or other tissues that surround the eye.  Many factors such as infection, allergy, surgery or trauma including blow to the eye, foreign body and chemical injury can lead to ocular inflammation. It is important to manage ocular pain, else it can affect other parts of eyes such as cornea, retina, sclera, conjunctiva and the vasculature. Ocular pain is caused by several conditions such as glaucoma, ocular herpes, shingles, optic neuritis, dry eye and refractive error.

Explore Report at: https://www.psmarketresearch.com/market-analysis/ocular-pain-treatment-market

Some of the key players operating in the global ocular pain market are ICON Bioscience Inc., Xigen S.A., Sylentis S.A., Bayer AG, Bristol Meyer Squibb Company, Merck and Co., Inc.,  Sun Pharmaceutical Industries Ltd., Reata Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc. and Ocular Therapeutix, Inc.